Launching Revvity: A Scientific Solutions Company Powering Innovation from Discovery to Cure
09 Mai 2023 - 2:00PM
Business Wire
- Transformation aimed at revolutionizing next generation
scientific breakthroughs that solve the world’s greatest health
challenges
- Trusted partner to pharma, government and diagnostics customers
with complete, end-to-end solutions
- To begin trading as RVTY under new name on May 16th (formerly
NYSE: PKI)
Revvity, Inc. officially launches today as a science-based
solutions company that leverages innovation across life sciences
and diagnostics to help improve lives everywhere. Born from two
words, “revolutionize” (rev) and “vita” (vit) meaning “life” in
Latin, Revvity delivers end-to-end expertise and solutions from
research discovery to development, and diagnosis to cure. The
Company was previously affiliated with PerkinElmer, Inc.
“The unveiling of Revvity is the capstone of a nearly year-long
journey that has transformed who we are and reinforces why our work
matters,” said Prahlad Singh, president and chief executive officer
of Revvity. “At Revvity, we are united with our customers to impact
health across the lifespan. Our purpose is to expand the boundaries
of human potential through science. We view the challenges facing
our customers as a call to action.”
Revvity provides reagents, consumables, assays, instruments and
software to customers in markets ranging from pharma and biotech,
diagnostic labs, academia and government agencies. “We’re a
translational company in the sense that our capabilities facilitate
decision making between research and clinical customers,” remarked
Singh. “With cross-business collaborations between our automation,
multi-omics offerings, and our Signals software business, we have
unique capabilities which put us in an optimal position to
accelerate breakthrough solutions – starting with preclinical
research and scientific discovery, all the way through to
diagnosing and helping to treat disease.”
Changes to Brand Architecture
- Industry leading franchises, BioLegend, EUROIMMUN, Tulip
Diagnostics and ViaCord retain their own names as unique product
lines.
- The Company’s comprehensive scientific software platform,
previously known as PerkinElmer Informatics, will become Revvity
Signals Software, Inc.
- Revvity Omics replaces PerkinElmer Genomics as the Company's
genomics services business.
- Cisbio, Horizon Discovery, Nexcelom Bioscience, Omni
International, Oxford Immunotec, SIRION Biotech and SonoVol will
now identify as Revvity, while maintaining their specific product
names.
Visit the “Our Story” page for more on the Company’s evolution
and download the corporate fact sheet to get a full list of facts
and figures.
What’s ahead?
- Revvity’s Q1 earnings webcast is scheduled on May 11, 2023 at
8:00 a.m. ET. Register here.
- The Company will trade under its new name and the stock ticker
symbol "RVTY” at market open on May 16, 2023. At the same time its
1.875% Notes due 2026 will begin trading under “RVTY 26.” Members
of the Revvity team will commemorate the new name, brand and stock
ticker by ringing the bell that morning at the New York Stock
Exchange. A livestream of the ceremony can be viewed here.
- Roadshows intended for existing and prospective customers will
be scheduled in select global markets to introduce the new brand
and latest innovations. Follow Revvity’s social media channels for
updates.
Factors Affecting Future Performance
This press release contains "forward-looking" statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including, but not limited to, statements relating to
estimates and projections of future earnings per share, cash flow
and revenue growth and other financial results, developments
relating to our customers and end-markets, and plans concerning
business development opportunities, acquisitions and divestitures.
Words such as "believes," "intends," "anticipates," "plans,"
"expects," “estimates,” "projects," "forecasts," "will" and similar
expressions, and references to guidance, are intended to identify
forward-looking statements. Such statements are based on
management's current assumptions and expectations and no assurances
can be given that our assumptions or expectations will prove to be
correct. A number of important risk factors could cause actual
results to differ materially from the results described, implied or
projected in any forward-looking statements. These factors include,
without limitation: (1) markets into which we sell our products
declining or not growing as anticipated; (2) the effect of the
COVID-19 pandemic on our sales and operations; (3) fluctuations in
the global economic and political environments; (4) our failure to
introduce new products in a timely manner; (5) our ability to
execute acquisitions and divestitures, license technologies, or to
successfully integrate acquired businesses and licensed
technologies into our existing business or to make them profitable,
or successfully divest businesses; (6) our ability to compete
effectively; (7) fluctuation in our quarterly operating results and
our ability to adjust our operations to address unexpected changes;
(8) significant disruption in third-party package delivery and
import/export services or significant increases in prices for those
services; (9) disruptions in the supply of raw materials and
supplies; (10) our ability to retain key personnel; (11)
significant disruption in our information technology systems, or
cybercrime; (12) our ability to realize the full value of our
intangible assets; (13) our failure to adequately protect our
intellectual property; (14) the loss of any of our licenses or
licensed rights; (15) the manufacture and sale of products exposing
us to product liability claims; (16) our failure to maintain
compliance with applicable government regulations; (17) regulatory
changes; (18) our failure to comply with healthcare industry
regulations; (19) economic, political and other risks associated
with foreign operations; (20) our ability to obtain future
financing; (21) restrictions in our credit agreements; (22)
significant fluctuations in our stock price; (23) reduction or
elimination of dividends on our common stock; and (24) other
factors which we describe under the caption "Risk Factors" in our
most recent annual report on Form 10-K and in our other filings
with the Securities and Exchange Commission. We disclaim any
intention or obligation to update any forward-looking statements as
a result of developments occurring after the date of this press
release.
About Revvity
At Revvity, “impossible” is inspiration, and “can’t be done” is
a call to action. Revvity provides health science solutions,
technologies, expertise and services that deliver complete
workflows from discovery to development, and diagnosis to cure.
Revvity is revolutionizing what’s possible in healthcare, with
specialized focus areas in translational multi-omics technologies,
biomarker identification, imaging, prediction, screening, detection
and diagnosis, informatics and more.
With 2022 revenue of more than $3 billion and over 11,000
employees, Revvity serves customers across pharmaceutical and
biotech, diagnostic labs, academia and governments. It is part of
the S&P 500 index and has customers in more than 190
countries.
Stay updated by following our Newsroom, LinkedIn, Twitter,
YouTube, Facebook and Instagram for updates.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230509005127/en/
Investor Relations: Steve Willoughby (781) 663-5677
steve.willoughby@revvity.com
Media Relations: Chet Murray (781) 663-5719
chet.murray@revvity.com
PerkinElmer (NYSE:PKI)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
PerkinElmer (NYSE:PKI)
Historical Stock Chart
Von Mai 2023 bis Mai 2024